Informations générales (source: ClinicalTrials.gov)
A Phase 1, Open-label Study of BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Interventional
Phase 1
Bristol-Myers Squibb (Voir sur ClinicalTrials)
octobre 2023
juillet 2031
03 septembre 2026
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy
of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Christophe MASSARD | 03/09/2026 20:15:05 | Contacter | ||
Critères
Homme
- Participant must have histologically or cytologically confirmed adenocarcinoma of
the prostate.
- Participant must have an Eastern Cooperative Oncology Group (ECOG) performance
status 0 to 1.
- Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
- Participant must have progressed on androgen deprivation therapy (ADT) and at least
one prior secondary hormonal therapy approved for castration-resistant prostate
cancer (CRPC)
Exclusion Criteria:
- Participant must not have history of brain metastases.
- Participant must not have impaired cardiac function or clinically significant
cardiac disease.
- Participant must not have any significant medical condition, including active or
uncontrolled infection, psychiatric illness, or the presence of laboratory
abnormalities, which places the participant at unacceptable risk or prevent
participation in the study based on Investigator assessment.
Other protocol-defined inclusion/exclusion criteria apply